Mixtard 30 to be discontinued in December

Mixtard 30 insulin products are to be discontinued by Novo Nordisk on 31 December, the company has announced.

There are currently around 90,000 patients on Mixtard 30. These patients will need to be moved to other insulin therapies.

Diabetes UK said it was ‘very disappointed about the withdrawal’, which it said was not in the best interests of people with diabetes.

Chief executive Douglas Smallwood, commented: ‘We think this is wrong and asked Novo Nordisk to reconsider their decision, considering the 90,000 or so people currently using Mixtard 30, but they argued they are committed to withdrawing all older types of human insulin over time. We then asked for a longer withdrawal period to ensure a properly co-ordinated response to this, but that proposal was also turned down.’

The charity said that, although there was no need for patients to panic, those needing to switch therapies should not wait until December to do so.

Manufacturer Novo Nordisk said it was aware, from practice level data, where patients treated with Mixtard 30 were based. ‘Novo Nordisk has provided detailed information and support to healthcare professionals to ensure patients are moved to an appropriate alternative insulin prior to 31 December 2010,’ a spokeswomen said. ‘In addition, Novo Nordisk will be working with people running diabetes clinics to assess the impact of this change and provide nurse support where appropriate.’

The company said that, by discontinuing Mixtard 30, it would be able to focus resources on ‘developing the next generation of insulins and further advancing diabetes care’.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus
Follow Us: